Zur Rose Group AG operates an e-commerce pharmacy and a wholesale business for medical and pharmaceutical products under the Zur Rose and DocMorris brands in Germany, Switzerland, and rest of Europe.
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has Zur Rose Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ROSE's share price has been volatile over the past 3 months.
7 Day Return
CH Consumer Retailing
1 Year Return
CH Consumer Retailing
Return vs Industry: ROSE exceeded the Swiss Consumer Retailing industry which returned 0.7% over the past year.
Return vs Market: ROSE exceeded the Swiss Market which returned 3.2% over the past year.
Price Volatility Vs. Market
How volatile is Zur Rose Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StMarket Sentiment Around Loss-Making Zur Rose Group AG (VTX:ROSE)
2 months ago | Simply Wall StDoes Zur Rose Group (VTX:ROSE) Have A Healthy Balance Sheet?
3 months ago | Simply Wall StZur Rose Group AG's (VTX:ROSE) Path To Profitability
Is Zur Rose Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ROSE (CHF188.8) is trading above our estimate of fair value (CHF63.34)
Significantly Below Fair Value: ROSE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ROSE is unprofitable, so we can't compare its PE Ratio to the Consumer Retailing industry average.
PE vs Market: ROSE is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ROSE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ROSE is overvalued based on its PB Ratio (4x) compared to the XE Consumer Retailing industry average (1.7x).
How is Zur Rose Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROSE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.2%).
Earnings vs Market: ROSE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ROSE's is expected to become profitable in the next 3 years.
Revenue vs Market: ROSE's revenue (19.7% per year) is forecast to grow faster than the Swiss market (2.4% per year).
High Growth Revenue: ROSE's revenue (19.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROSE's Return on Equity is forecast to be low in 3 years time (3.7%).
How has Zur Rose Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ROSE is currently unprofitable.
Growing Profit Margin: ROSE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ROSE is unprofitable, and losses have increased over the past 5 years at a rate of -54.7% per year.
Accelerating Growth: Unable to compare ROSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ROSE is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (2.3%).
Return on Equity
High ROE: ROSE has a negative Return on Equity (-12.92%), as it is currently unprofitable.
How is Zur Rose Group's financial position?
Financial Position Analysis
Short Term Liabilities: ROSE's short term assets (CHF428.1M) exceed its short term liabilities (CHF212.6M).
Long Term Liabilities: ROSE's short term assets (CHF428.1M) exceed its long term liabilities (CHF373.6M).
Debt to Equity History and Analysis
Debt Level: ROSE's debt to equity ratio (78.8%) is considered high.
Reducing Debt: ROSE's debt to equity ratio has increased from 74.6% to 78.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ROSE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ROSE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Zur Rose Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ROSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ROSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ROSE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ROSE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ROSE is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ROSE's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Walter Oberhänsli (61yo)
Mr. Walter Oberhänsli serves as the Chief Executive Officer at Zur Rose Group AG since 2005. and served as its and Executive Director. Mr. Oberhänsli served as Member of the Executive Board. He served as C ...
CEO Compensation Analysis
Compensation vs Market: Walter's total compensation ($USD1.27M) is about average for companies of similar size in the Swiss market ($USD1.26M).
Compensation vs Earnings: Walter's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||15.42yrs||CHF1.22m||1.23% CHF23.1m|
|Chief Financial Officer||5.58yrs||no data||0.49% CHF9.1m|
|Chief Operations Officer||0.083yr||no data||no data|
|Head of Corporate Communications||no data||no data||no data|
|Head of Germany & Head of B2C||no data||no data||0.42% CHF7.9m|
|Head of Switzerland||no data||no data||0.43% CHF7.9m|
|Chief Strategy and Digital Officer||0.58yr||no data||no data|
|Head of Europe||0.083yr||no data||no data|
Experienced Management: ROSE's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
|CEO & Executive Director||15.42yrs||CHF1.22m||1.23% CHF23.1m|
|Non-Executive Director||1.08yrs||CHF69.00k||0.0020% CHF37.6k|
|Chairman of the Board of Directors||no data||CHF321.00k||0.73% CHF13.6m|
|Non-Executive Director||1.08yrs||CHF58.00k||0.0020% CHF37.6k|
|Non Executive Director||1.08yrs||CHF64.00k||0.023% CHF427.3k|
|Non-Executive Director||10.42yrs||CHF144.00k||0.056% CHF1.1m|
|Vice Chairman of the Board of Directors||no data||CHF161.00k||0.31% CHF5.8m|
Experienced Board: ROSE's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.
Zur Rose Group AG's company bio, employee growth, exchange listings and data sources
- Name: Zur Rose Group AG
- Ticker: ROSE
- Exchange: SWX
- Founded: 1993
- Industry: Drug Retail
- Sector: Consumer Retailing
- Market Cap: CHF1.868b
- Shares outstanding: 9.59m
- Website: https://www.zurrosegroup.com
Number of Employees
- Zur Rose Group AG
- Walzmühlestrasse 60
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ROSE||SWX (SIX Swiss Exchange)||Yes||Share Capital||CH||CHF||Jul 2017|
|0RRB||LSE (London Stock Exchange)||Yes||Share Capital||GB||CHF||Jul 2017|
|ZRE||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Jul 2017|
|ZRSE.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Jul 2017|
Zur Rose Group AG operates an e-commerce pharmacy and a wholesale business for medical and pharmaceutical products under the Zur Rose and DocMorris brands in Germany, Switzerland, and rest of Europe. The company offers consumer health, beauty, and personal care products. It also provides medicines management services. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals. In addition, it operates stationary pharmacy shops. The company was formerly known as Zur Rose AG and changed its name to Zur Rose Group AG in May 2015. Zur Rose Group AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/03 22:21|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.